These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 28521079)

  • 1. Association between CYP4F2 genotype and circulating plasma vitamin K concentration in children on chronic warfarin therapy: Possible long-term implications for bone development and vascular health.
    Kampouraki E; Avery PJ; Biss T; Kamali F
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28521079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Ketoconazole, a CYP4F2 Inhibitor, and CYP4F2*3 Genetic Polymorphism on Pharmacokinetics of Vitamin K
    Park JW; Kim KA; Park JY
    J Clin Pharmacol; 2019 Nov; 59(11):1453-1461. PubMed ID: 31134657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of CYP4F2 polymorphism on response to warfarin during induction phase: a prospective, open-label, observational cohort study.
    Bejarano-Achache I; Levy L; Mlynarsky L; Bialer M; Muszkat M; Caraco Y
    Clin Ther; 2012 Apr; 34(4):811-23. PubMed ID: 22417713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dietary and genetic influences on hemostasis in a Yup'ik Alaska Native population.
    Au NT; Reyes M; Boyer BB; Hopkins SE; Black J; O'Brien D; Fohner AE; Yracheta J; Thornton T; Austin MA; Burke W; Thummel KE; Rettie AE
    PLoS One; 2017; 12(4):e0173616. PubMed ID: 28376131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional Characterization of 29 Cytochrome P450 4F2 Variants Identified in a Population of 8380 Japanese Subjects and Assessment of Arachidonic Acid
    Sato Y; Hishinuma E; Yamazaki S; Ueda A; Kumondai M; Saito S; Tadaka S; Kinoshita K; Nakayoshi T; Oda A; Maekawa M; Mano N; Hirasawa N; Hiratsuka M
    Drug Metab Dispos; 2023 Dec; 51(12):1561-1568. PubMed ID: 37775333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy.
    Zhang JE; Jorgensen AL; Alfirevic A; Williamson PR; Toh CH; Park BK; Pirmohamed M
    Pharmacogenet Genomics; 2009 Oct; 19(10):781-9. PubMed ID: 19741565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450-dependent catabolism of vitamin K: ω-hydroxylation catalyzed by human CYP4F2 and CYP4F11.
    Edson KZ; Prasad B; Unadkat JD; Suhara Y; Okano T; Guengerich FP; Rettie AE
    Biochemistry; 2013 Nov; 52(46):8276-85. PubMed ID: 24138531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
    Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.
    Borgiani P; Ciccacci C; Forte V; Sirianni E; Novelli L; Bramanti P; Novelli G
    Pharmacogenomics; 2009 Feb; 10(2):261-6. PubMed ID: 19207028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population.
    Kudzi W; Ahorhorlu SY; Dzudzor B; Olayemi E; Nartey ET; Asmah RH
    BMC Res Notes; 2016 Dec; 9(1):507. PubMed ID: 27938396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients.
    Zhong SL; Yu XY; Liu Y; Xu D; Mai LP; Tan HH; Lin QX; Yang M; Lin SG
    Pharmacogenet Genomics; 2012 Mar; 22(3):176-82. PubMed ID: 22198820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of Stratified and Personalized Medicine Based on Pharmacogenomic and Pharmacokinetic Analyses].
    Hirai K
    Yakugaku Zasshi; 2019; 139(10):1253-1258. PubMed ID: 31582608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel polymorphisms in CYP4F2 and VKORC1 may lead to adaptations to the warfarin-dosage algorithm.
    Pharmacogenomics; 2013 Jul; 14(9):1003. PubMed ID: 23837473
    [No Abstract]   [Full Text] [Related]  

  • 15. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism.
    Wells PS; Majeed H; Kassem S; Langlois N; Gin B; Clermont J; Taljaard M
    Thromb Res; 2010 Jun; 125(6):e259-64. PubMed ID: 20421126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of gene polymorphims on the warfarin treatment at initial stage.
    Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS
    Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interindividual variability in sensitivity to warfarin--Nature or nurture?
    Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
    Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the
    Sun X; Yu WY; Ma WL; Huang LH; Yang GP
    Biomed Rep; 2016 Apr; 4(4):498-506. PubMed ID: 27073641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphism of cytochrome P450 4F2, vitamin E level and histological response in adults and children with nonalcoholic fatty liver disease who participated in PIVENS and TONIC clinical trials.
    Athinarayanan S; Wei R; Zhang M; Bai S; Traber MG; Yates K; Cummings OW; Molleston J; Liu W; Chalasani N
    PLoS One; 2014; 9(4):e95366. PubMed ID: 24759732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational analysis of missense variant CYP4F2*3 (V433M) in association with human CYP4F2 dysfunction: a functional and structural impact.
    Farajzadeh-Dehkordi M; Mafakher L; Samiee-Rad F; Rahmani B
    BMC Mol Cell Biol; 2023 May; 24(1):17. PubMed ID: 37161313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.